pi3k-inhibitor
(3)
Scorpion Therapeutics
Scorpion Therapeutics was a Boston-based, clinical-stage precision oncology company built to advance what it called "Precision Oncology 2.0" - pairing cancer biology, computational chemistry, medicinal chemistry and genomics to design small-molecule drugs against cancer targets that had resisted earlier approaches. Founded in 2020 by a group of prominent scientists and biotech operators, it raised more than $440 million and built a pipeline of mutant-selective inhibitors, most notably the PI3K-alpha inhibitor STX-478 and a franchise of fourth-generation EGFR inhibitors. In January 2025 Eli Lilly agreed to acquire the company and its PI3K-alpha program in a deal worth up to $2.5 billion, while Scorpion's remaining pipeline and staff were spun into a new independent company, Antares Therapeutics.
Synnovation Therapeutics
Synnovation Therapeutics is a Wilmington, Delaware precision medicine company building small-molecule cancer drugs aimed at validated oncology targets where greater potency and selectivity could beat the current standard of care. Founded in 2024 by a team of former Incyte medicinal chemistry leaders, it launched with a $102 million Series A led by Third Rock Ventures. Its lead programs are SNV1521, a CNS-penetrant, highly selective PARP1 inhibitor, and SNV4818, a mutant-selective PI3K-alpha inhibitor whose subsidiary Pikavation Therapeutics was acquired by Novartis in March 2026 for $2 billion upfront.
Totus Medicines
Totus Medicines is a clinical-stage precision medicines company in Emeryville, California, building covalent small-molecule drugs against historically undruggable targets. Its AI-powered OmniDEL platform screens billions of DNA-encoded covalent candidates against thousands of targets inside living cells, surfacing molecules that older methods miss. Its lead program, TOS-358, is the first and only covalent PI3Ka inhibitor in clinical development, showing class-leading tolerability and strong disease control in breast, endometrial, and head & neck cancers.